| Literature DB >> 34053584 |
Hossein Shooli1, Reza Nemati2, Hojjat Ahmadzadehfar3, Mariam Aboian4, Esmail Jafari1, Narges Jokar1, Iraj Nabipour5, Habibollah Dadgar6, Ali Gholamrezanezhad7, Mykol Larvie8, Majid Assadi9.
Abstract
Theranostic nuclear oncology, mainly in neuro-oncology (neurotheranostics), aims to combine cancer imaging and therapy using the same targeting molecule. This approach tries to identify patients who are most likely to benefit from tumor molecular radionuclide therapy. The ability of radioneurotheranostic agents to interact with cancer cells at the molecular level with high specificity can significantly improve the effectiveness of cancer therapy. A variety of biologic targets are under investigation for treating brain tumors. PET-based precision imaging can substantially improve the therapeutic efficacy of radiotheranostic approach in brain tumors.Entities:
Keywords: Brain tumor; Neuro-oncology; Neurotheranostics; PET/CT; PET/MR imaging; Radioneurotheranostics; Theranostics
Mesh:
Year: 2021 PMID: 34053584 DOI: 10.1016/j.cpet.2021.03.005
Source DB: PubMed Journal: PET Clin ISSN: 1556-8598